欧洲中部夏令时间2023年9月28日，欧洲内科肿瘤学会（ESMO）公布了即将召开的2023年ESMO大会上最为重磅的摘要LBAs（Late- Breaking Abstracts）标题及相关信息，覆盖Presidential Symposium（主席大会）、Proffered Paper Session（优选论文会议）以及Mini Oral Session（简短口头摘要会议）等会议摘要信息。
此次会议，肺癌领域迎来多项重磅研究结果的公布及更新。据【肿瘤资讯】统计，肺癌（包括胸部肿瘤）领域LBAs多达29项，其中，中国研究为4项。【肿瘤资讯】特将摘要信息整理如下，邀您同览！
主席大会专场
Presidential 1
摘要号：LBA1
CheckMate 77T: Phase 3 study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIB NSCLC
标题：III期CheckMate 77T研究：比较新辅助纳武利尤单抗+化疗与新辅助安慰剂+化疗和辅助纳武利尤单抗与辅助安慰剂一线治疗可切除II-IIIB期NSCLC
讲者：Tina Cascone (Houston, United States of America)
摘要号：LBA2
ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
标题：ALINA研究：早期ALK+ NSCLC 患者采用阿来替尼辅助治疗对比化疗的疗效和安全性
讲者：Ben J. Solomon (Melbourne, Australia)
摘要号：LBA3
Randomized Phase 3 Study of Selpercatinib versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer
标题：随机化III期研究：Selpercatinib对比Cabozantinib或Vandetanib治疗晚期、激酶抑制剂初治、RET突变甲状腺髓样癌
讲者：Julien Hadoux (Villejuif, Cedex, France)
摘要号： LBA4
Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC
标题：随机化III期研究：Selpercatinib对比化疗和帕博利珠单抗一线治疗RET融合阳性NSCLC
讲者：Herbert Ho Fung Loong (Sha Tin, Hong Kong PRC)
摘要号： LBA5
Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study
标题：全球随机化III期PAPILLON 研究的初步结果：Amivantamab联合化疗对比化疗一线治疗EGFR 外显子20插入突变的晚期NSCLC
讲者：Nicolas Girard (Paris, France)
Presidential 3
摘要号： LBA12
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01
标题：随机化III期TROPION-Lung01研究结果：Datopotamab deruxtecan（Dato-DXd）对比多西他赛治疗既往接受过治疗的晚期/转移性NSCLC
讲者：Aaron E. Lisberg (Los Angeles, United States of America)
摘要号： LBA14
Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial
标题：全球随机对照III期MARIPOSA研究的初步结果：Amivantamab联合Lazertinib对比奥希替尼一线治疗EGFR突变的晚期NSCLC
讲者：Byoung Chul Cho (Seoul, Korea, Republic of)
摘要号： LBA15
Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated Advanced NSCLC After Progression on Osimertinib: MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial
标题：全球随机对照III期MARIPOSA-2研究：Amivantamab联合化疗（联合或不联合Lazertinib）对比化疗用于奥希替尼治疗进展后的EGFR突变晚期 NSCLC
讲者：Antonio Passaro (Milan, Italy)
优选论文专场
转移性NSCLC
摘要号： LBA63
SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
标题：III期SAPPHIRE研究：Sitravatinib+纳武利尤单抗对比多西他赛治疗既往接受过治疗的晚期非鳞NSCLC
讲者：Hossein Borghaei (Philadelphia, United States of America)
摘要号：LBA64
Overall Survival from a Phase II Randomised Double-Blind Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC
标题：II期PERLA研究：Dostarlimab+CT对比帕博利珠单抗+ CT治疗转移性非鳞NSCLC的总生存期公布
讲者：Solange Peters (Lausanne, Switzerland)
摘要号： LBA65
KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
标题：KRYSTAL-7研究：Adagrasib联合帕博利珠单抗一线治疗携带KRASG 12 C突变的晚期NSCLC患者的疗效和安全性
讲者：Marina C. Garassino (Chicago, United States of America)
摘要号：LBA66
Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: a phase III study (ACHILLES/TORG1834)
标题：III期ACHILLES/TORG 1834研究：阿法替尼对比化疗一线治疗伴有致敏性罕见EGFR突变的NSCLC
讲者：Satoru Miura (Niigata, Japan)
摘要号：LBA67
A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)
标题：III期ATTLAS，KCSG-LU 19 -04研究：阿替利珠单抗联合贝伐珠单抗和化疗治疗EGFR或ALK突变的NSCLC
讲者：Myung-Ju Ahn (Seoul, Korea, Republic of)
非转移性NSCLC和其他胸部恶性肿瘤
摘要号：LBA56
Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
标题：KEYNOTE-671研究：早期NSCLC围手术期帕博利珠单抗治疗的总生存期
讲者：Jonathan D. Spicer (Montreal, Canada)
摘要号：LBA60
Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer
标题：立体定向体部放疗联合序贯免疫化疗新辅助治疗可切除非小细胞肺癌
讲者：赵泽锐（中山大学肿瘤防治中心）
摘要号：LBA98
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial
标题：II期RELEVENT研究：雷莫西尤单抗联合卡铂和紫杉醇治疗未经治疗的转移性胸腺癌的疗效和安全性
讲者：Claudia Proto (Milan, Italy)
摘要号：LBA92
Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase 2 DeLLphi-301 study
标题：II期DeLLphi-301研究的初步分析：Tarlatamab用于既往接受过治疗的小细胞肺癌（SCLC）患者
讲者：Luis Paz-Ares (Madrid, Spain)
简短口头报告专场
转移性NSCLC
摘要号：LBA68
FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
标题：FLAURA2研究：奥希替尼±化疗一线治疗EGFRm晚期NSCLC的安全性和CNS结局
讲者：David Planchard (Villejuif, Cedex, France)
摘要号：LBA69
Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): a randomized multicenter study
标题：一项随机多中心研究：阿美替尼联合阿帕替尼对比阿美替尼一线治疗EGFR突变局部晚期或转移性NSCLC患者
讲者：胡毅（中国人民解放军总医院）
摘要号：LBA70
OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)
标题：多中心、开放标签、随机化II期OSIRAM-1/TORG 1833研究：奥希替尼联合雷莫西尤单抗对比奥希替尼单药治疗EGFR突变非鳞非小细胞肺癌
讲者：Yoshiro Nakahara (Sagamihara, Japan)
摘要号：LBA71
A Multi-Centre Open-Label Randomized Phase II Study of Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC (RAMOSE trial interim analysis)
标题：多中心、开放标签、随机化、II期RAMOSE试验中期分析：比较奥希替尼联合/不联合雷莫西尤单抗一线治疗EGFR突变转移性NSCLC
讲者：Xiuning Le (Houston, United States of America)
摘要号：LBA72
DARWIN II: Deciphering Anti-tumour Response and Resistance to immunotherapy With INtratumour Heterogeneity in NSCLC
标题：DARWIN II：解读NSCLC肿瘤内异质性的抗肿瘤反应和免疫治疗耐药性
讲者：Crispin Hiley (London, United Kingdom)
非转移性NSCLC和其他胸部恶性肿瘤
摘要号：LBA99
First survival data from the NIPU trial; A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
标题：NIPU试验的首批生存数据：一项随机、开放标签、II期研究，评估纳武利尤单抗和伊匹木单抗联合UV1疫苗二线治疗恶性间皮瘤患者
讲者：Aaslaug Helland (Oslo, Norway)
摘要号：LBA93
EXTENTORCH: a randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)
标题：III期EXTENTORCH研究：特瑞普利单抗对比安慰剂联合化疗一线治疗广泛期小细胞肺癌（ES-SCLC）患者
讲者：柳影（吉林省肿瘤医院）
摘要号：LBA57
Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase 3 CheckMate 816 study: 3-y results by tumor PD-L1 expression
标题：III期CheckMate 816研究中PD-L1表达的3年随访结果：新辅助纳武利尤单抗+化疗
讲者：Mariano Provencio Pulla (Majadahonda, Spain)
摘要号：LBA58
Pathological Response to Neoadjuvant Tislelizumab (TIS) Plus Platinum-Doublet (PtDb) Chemotherapy (CT) in Resectable Stage II-IIIA NSCLC Patients (pts) in the Phase 3 (Ph3) RATIONALE-315 Trial
标题：III期RATIONALE-315研究：可切除的II-IIIA期NSCLC患者对新辅助替雷利珠单抗联合双铂化疗的病理学缓解
讲者：岳东升（天津医科大学肿瘤医院）
摘要号：LBA59
Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase 3 AEGEAN trial
标题：III期AEGEAN研究：可切除NSCLC患者ctDNA清除率和病理学缓解与新辅助治疗的相关性
讲者：Martin Reck (Grosshansdorf, Germany)
摘要号：LBA61
Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III NSCLC: Final analysis from PACIFIC-6
标题：PACIFIC-6研究的最终分析：不可切除的III期NSCLC患者序贯放化疗（CRT）后使用度伐利尤单抗
讲者：Marina C. Garassino (Chicago, United States of America)
摘要号：LBA62
Durvalumab after radiotherapy (RT) in patients with unresectable Stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study
标题：DUART研究的初步结果：不适合化疗的不可切除的III期NSCLC患者放疗（RT）后使用度伐利尤单抗
讲者：Andrea Riccardo R. Filippi (Pavia, Italy)
（以上内容排名不分先后。如有遗漏或错误，敬请指正。）
https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session
排版编辑：Nydia
苏公网安备32059002004080号
